27,380 Alzheimer's and dementia studies in plain English, each scored out of 100.
We describe the largest series of patients with TARDBP mutations presenting with frontotemporal dementia (FTD) and review the cases in the literature to precisely characterize FTD diseases associated with this genotype. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Hypertension is a highly prevalent condition with numerous health risks, and the incidence of hypertension is greatest among older adults. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Disturbance of the polyubiquitinylation machinery may be a key feature of aging and neurodegeneration. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
There is accumulating evidence suggesting that changes in brain perfusion are present long before the clinical symptoms of Alzheimer's disease (AD), perhaps even before amyloid-β accumulation or brain atrophy. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
We propose that brain energy deficit is an important pre-symptomatic feature of Alzheimer's disease (AD) that requires closer attention in the development of AD therapeutics. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Our findings suggest that restoration of the expression of nuclear-encoded OXPHOS genes in aging could be a viable strategy for blunting AD progression. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Chicoric acid (CA), a natural phenolic acid extracted from chicory and the echinacea (purple coneflower) plant ( Echinacea purpurea ), has been regarded as a nutraceutical that has powerful antioxidant and antiobesity activities. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Alzheimer's disease (AD) is a multifactorial disease with genetic (70%) and environmental (30%) causes. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Positron emission tomography (PET) with the glucose analog F-18-fluorodeoxyglucose (FDG) is widely used in the diagnosis of neurodegenerative diseases. 4 key findings →
Participants: 77 Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Brain diseases and disorders such as Alzheimer disease, Parkinson disease, depression, schizophrenia, autism, and addiction lead to reduced quality of daily life through abnormal thoughts, perceptions, emotional states, and behavior. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Dementia SMRs were higher in northern than central or southern Italy. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Cognitive decline is an increasingly important public health problem, with more than 100 million adults worldwide projected to develop dementia by 2050. 2 key findings →
Evidence: high
Full summary, score breakdown and related studies → Original source
Alzheimer's disease (AD) is the most common type of dementia among the elderly. 2 key findings →
Participants: 30 Evidence: low
Full summary, score breakdown and related studies → Original source
Advance care planning can assist patients to achieve a sense of control and 'peace of mind' and facilitates important family discussion. 2 key findings →
Design: cross-sectional Evidence: low
Full summary, score breakdown and related studies → Original source
True predictors can be identified by repeatedly dividing data into fitting/validating subsets and referring the final model based on summarizing results. 3 key findings →
Evidence: moderate
Full summary, score breakdown and related studies → Original source
When an individual has dementia, family members are involved in many care transitions in their roles as caregivers. 1 key finding →
Participants: 24 Evidence: low
Full summary, score breakdown and related studies → Original source
Alzheimer's disease (AD) researchers commonly use MRI as a quantitative measure of disease severity. 5 key findings →
Evidence: moderate
Full summary, score breakdown and related studies → Original source
Multifactorial mechanisms underlying late-onset Alzheimer's disease (LOAD) are poorly characterized from an integrative perspective. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
It is not known whether computerized cognitive assessments, like the CogState battery, are sensitive to preclinical cognitive changes or pathology in people at risk for Alzheimer's disease(AD). 4 key findings →
Participants: 71 Evidence: low
Full summary, score breakdown and related studies → Original source
Excellent reliability was observed among the 6 C3-PAD alternate versions (Cronbach alpha coefficient=0.93). 5 key findings →
Participants: 49 Evidence: low
Full summary, score breakdown and related studies → Original source
A common approach to understanding neurodegenerative disease is comparing gene expression in diseased versus healthy tissues. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
Tau positron emission tomography ligands provide the novel possibility to image tau pathology in vivo However, little is known about how in vivo brain uptake of tau positron emission tomography ligands relates to tau aggregates observed post-mortem. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
Although historically perceived as a disorder confined to the brain, our understanding of Alzheimer's disease (AD) has expanded to include extra-cerebral manifestation, with mounting evidence of abnormalities in the eye. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Non-steroidal anti-inflammatory drugs (NSAIDs) inhibit cyclooxygenase-1 (COX-1) and COX-2 enzymes. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
Raising awareness of this unique disability is imperative to insure that individuals receive the necessary rehabilitation and supportive services to improve their level of independence and quality of life. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 27,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,380 records, built mostly from automated pulls of Europe PMC (60.6% of the library) and OpenAlex (18.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,032 records (3.8% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →